CLINICAL TRIALS PROFILE FOR TRIAMTERENE AND HYDROCHLOROTHIAZIDE
✉ Email this page to a colleague
All Clinical Trials for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000525 ↗ | Diuretics, Hypertension, and Arrhythmias Clinical Trial | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1986-07-01 | To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death. |
| NCT00000525 ↗ | Diuretics, Hypertension, and Arrhythmias Clinical Trial | Completed | University of California, San Francisco | Phase 3 | 1986-07-01 | To determine whether hypertensive patients with ECG abnormalities and receiving hydrochlorothiazide diuretics were at increased risk of sudden death. |
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT01661777 ↗ | Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops | Withdrawn | Vanderbilt University | N/A | 2012-08-01 | The purpose of this study is to evaluate the benefit of treatment of refractory Eustachian tube dysfunction with standard treatment for endolymphatic hydrops. Eustachian tube dysfunction is a common diagnosis made in otolaryngology related to abnormal pressure equalization of the middle ear space related to a swollen, inflamed, or occluded Eustachian tube. The symptoms of this include perceived hearing loss, a feeling of fullness in the affected ear/ears, ear pain, ear popping, and occasionally imbalance. These symptoms overlap with a more rare and difficult to diagnose condition known as endolymphatic hydrops, or an overproduction to fluid in the inner ear. The treatment for these two conditions are distinct and traditionally, patients are treated for Eustachian tube dysfunction first as it is much more common and there are several treatments, namely nasal steroids, antihistamines, and pressure equalization tubes. For patients who do not improve with these treatments, they are often treated with diuretics and a low salt diet to treat for supposed endolymphatic hydrops. There has never been a study to investigate the utility of these treatments in patients with refractory Eustachian tube dysfunction. There is also reason to believe that chronic ETD with effusion can lead to both inner and middle ear dysfunction. Thus, this study aims to determine the benefit of standard endolymphatic hydrops treatment on patient with refractory Eustachian tube dysfunction symptoms in a prospective fashion. Hypothesis: Patients with refractory Eustachian tube dysfunction (patients with no or minimal symptom improvement despite nasal steroid and antihistamine treatment followed by myringotomy tube placement) have an element of endolymphatic hydrops and these patient's symptoms will improve with a low sodium diet and diuretic. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Condition Name
Clinical Trial Locations for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Trials by Country
Clinical Trial Progress for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Clinical Trial Phase
Clinical Trial Sponsors for TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Sponsor Name
| Sponsor Name for TRIAMTERENE AND HYDROCHLOROTHIAZIDE | |
| Sponsor | Trials |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| University of California, San Francisco | 1 |
| US Department of Veterans Affairs | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
